Member Info for HideInPlainSight

Thanks. That's compelling percentage, just wondering if the change to trial design might impact how we can extrapolate P2 results. I'm excited (impatient) to find out.

Great RNS yesterday, pleased to get the update.

In light of the change in primary end points from osci, how do people think this changes the probability of P3 success?

I may be making this up but thought I'd read finncap adjust chance accordingly thanks to a post on this forum.

Just doing a risk/reward review and the adjustment to endpoints is my only area of internal debate!

As a holder who is most excited by sng001 as the next generation of preventative at home treatment for viral complications in COPD and other vulnerable groups (in which I have high conviction) it's the hospital trials I need to understand more in respect of the change in endpoints... Any thoughts appreciated.